Trial Profile
Pilot Trial of Enasidenib (AG-221) Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients With IDH2 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Enasidenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 29 Jan 2024 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
- 29 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 15 Dec 2024.
- 07 Sep 2023 Planned End Date changed from 15 Jun 2023 to 15 Dec 2023.